ProAir RespiClick FDA Approval History
FDA Approved: Yes (First approved March 31, 2015)
Brand name: ProAir RespiClick
Generic name: albuterol sulfate
Dosage form: Inhalation Powder
Company: Teva Pharmaceutical Industries Ltd.
Treatment for: Asthma
ProAir RespiClick (albuterol sulfate) is a breath-actuated, dry-powder, short-acting beta-agonist (SABA) inhaler for the relief of acute asthma symptoms.
Development timeline for ProAir RespiClick
| Date | Article |
|---|---|
| Apr 29, 2016 | Approval Teva Announces FDA Approval of ProAir RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11 |
| Apr 1, 2015 | Approval Teva Announces FDA Approval of ProAir RespiClick |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
